NEW YORK, March 29 – Invitrogen said Thursday it has settled pending patent infringement suits against Promega and two other competitors, New England Biolabs and Display Systems Biotech, in which Invitrogen alleged that its competitors had infringed on its patents for modified reverse transcriptase enzymes with low RNase activity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.